EPIX (ESSA Pharma Inc) Projected Price to Earnings

Corporate company logo of ESSA Pharma (EPIX)

ESSA Pharma Inc. (EPIX) develops targeted prostate cancer treatments based on mazophanten data. The company's expected P/E valuation illustrates the market reaction to these catalysts, where 0.00 serves as the base parameter value. Long-term platform patents provide monopoly potential, while fully utilized research capacities and precision analysis ensure development stability.

Projected Price to Earnings Ratio: essapharma.com (EPIX) for 07/04/2022 - 10/25/2025

Summary analytical data breakdowns for ESSA Pharma Inc (EPIX)

- current price and projected stock value:
Stock Quotes ESSA Pharma Inc.|EPIX - Fair Value Consensus
- business market valuation indicators:
Market Valuation ESSA Pharma, Inc.|EPIX - Real Price to Acquire Entire Company
- issuer book value statistics:
Net Assets per Single Share ESSA Pharma|EPIX - Total Stockholders' Equity|Market Value to Book Value Ratio essapharma.com|EPIX - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital ESSA Pharma Inc.|EPIX - Long-Term Liabilities to Capital|Short-Term Debt to Equity ESSA Pharma Inc.|EPIX - Company Aggregate Debt|Debts to Book Capitalization ESSA Pharma, Inc.|EPIX - Long-Term Debt|Company Short-Term Debt ESSA Pharma|Quick Liquidity essapharma.com
- company profitability and valuation multiples indicators:
EPIX - Net Financial Result|Projected Future Earnings ESSA Pharma Inc.|EPIX - P/E Multiple|Projected Price to Earnings ESSA Pharma Inc.|EPIX - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ESSA Pharma, Inc.|EPIX - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) ESSA Pharma|EPIX - Earnings per share for the trailing year|Quarterly EPS earnings growth essapharma.com|EPIX - Earnings growth in current year|Net earnings per share growth forecast for next year ESSA Pharma Inc.
Summary company analytics:ESSA Pharma
Brand item of ESSA Pharma Inc.

For the non-cyclical business of ESSA Pharma Inc. (EPIX), where demand for oncology therapy remains stable, the forward P/E multiple serves as an indicator of market expectations regarding future earnings. The ratio of market capitalization to projected net income allows for an assessment of the extent to which the success of clinical trials is priced in, helping investors determine whether the company's current valuation is inflated relative to its fundamental prospects.

Competitors of ESSA Pharma Inc. (EPIX)

Projected Price to Earnings MRUS (Merus)|IMMP (Immutep Ltd) - Future Price to Earnings Multiple|Anixa Biosciences Inc - Projected Price to Earnings|ATOS - Projected Price to Earnings|CNTX - Future Price to Earnings|Projected Price to Earnings Ratio Mersana Therapeutics|BriaCell (BCTX) - Future Price to Earnings|Projected Price to Earnings QT Imaging Holdings